LCTX

Lineage Cell Therapeutics, Inc.

1.01 USD

Last updated Dec 6, 00:36 UTC

Yesterday HIGH

$1.02

Yesterday LOW

$0.98

52w HIGH

$1.58

52w LOW

$0.93

EPS

-0.04

PE

-25.25

Next Earnings

Mar 7, 2024

Overview News Government Trades

Lineage Cell Therapeutics, Inc. stock is down -6.48% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 31 December’s closed higher than November.

OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, are in clinical trials to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.

Stock Exchange

NYSE MKT

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Carlsbad , United States Of America

Website

lineagecell.com

Benzinga Insights

Thu May 11, 2023

Lineage Cell Therapeutics: Q1 Earnings Insights
Benzinga Newsdesk

Thu May 11, 2023

Lineage Cell Therapeutics Q1 EPS $(0.03) Vs. $(0.04) Prior Year, Sales $2.39M Beat $2.01M Estimate

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of
Benzinga Insights

Thu May 11, 2023

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
Benzinga Newsdesk

Wed Apr 26, 2023

Lineage Cell Therapeutics, Inc. Highlights Presentation Of RG6501 Phase 1/2a Data At ARVO 2023

Preliminary Evidence of Durable Anatomical and Functional Improvements Following Administration of OpRegen Cells Extensive OpRegen Surgical Bleb Coverage of Areas of GA May Be Critical for Optimizing Patient
richadhand@benzinga.com

Wed Apr 26, 2023

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $7 price target.
Lisa Levin

Thu Apr 13, 2023

Harley-Davidson, Sportsman's Warehouse And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Benzinga Insights

Tue Mar 14, 2023

Lineage Cell Therapeutics's Return On Capital Employed Overview
richadhand@benzinga.com

Fri Mar 10, 2023

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $7 price target.
Happy Mohamed

Thu Mar 9, 2023

Lineage Cell Therapeutics Q4 EPS $(0.03) Beats $(0.04) Estimate, Sales $1.90M Miss $2.57M Estimate

Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 82.35 percent increase over losses of $(0.17) per share
Benzinga Insights

Thu Mar 9, 2023

Earnings Scheduled For March 9, 2023

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.